Pain Management Drugs Market, by Drug Class (Opioids, NSAIDs, Anticonvulsants, Antidepressants, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jul 2022

Code : CMI1697

Pages :205

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Global Pain Management Drugs Market: Restraint

The major factors that hinder growth of the global pain management drugs market include side effects associated with the pain management drugs and addiction issues with the opioid medications. For instance, in January 2022, according to National Institute on Drug Abuse, an opioid overdose can be reversed with the drug naloxone when administered. Improvements have been seen in some regions of the U.S. in the form of decreasing availability of prescription opioid pain relievers and decreasing misuse among the countries teenagers. However, since 2017, overdose deaths involving heroin increased dramatically.

High prevalence of chronic pain diseases is expected to drive growth of the pain management drugs market over the forecast period.

Increasing prevalence of chronic pain diseases is expected to drive growth of the pain management drugs market over the forecast period. For instance, in February 2022, according to data published by National Center for Biotechnology Information, the Centers for Disease Control and Prevention (CDC) used data from the 2019 National Health Interview Survey (NHIS) to estimate that 50.2 million U.S. adults experienced chronic pain. A second CDC publication from National Health Interview Survey (NHIS) found that 22.1% of these U.S. adults with chronic pain used prescription opioids.

Moreover, in February 2022, according to data published by National Health Interview Survey (NHIS), the prevalence of chronic pain was 20.4% globally, and the prevalence of high-impact chronic pain was 7.4% (or 36.4% of adults who had chronic pain). Chronic pain was highest among women (21.7%), non-Hispanic white adults (23.6%), and those aged 65 and over (30.8%) overall globally.

Global Pain Management Drugs Market: Key Developments

In April 2022, Eli Lilly and Company, a pharmaceutical company, Eli Lilly and Company passed phase II trial for LY3556050, a small molecule Somatostatin receptor type 4 (SSTR4 agonist). LY3556050, is designed to modulate somatostatin signaling, impacting nerve excitability, resulting in improved regulation of inflammation and pain. It is being developed for treatment of pain. Somatostatin receptor type 4 is a protein encoded by the SSTR4 gene.

In April 2022, Eli Lilly and Company, a pharmaceutical company, passed phase II trial for LY3526318, an oral, highly selective, small molecule antagonist of transient receptor potential ankyrin 1 (TRPA1). LY3526318 is a calcium-permeable nonselective cation channel expressed in pain sensing peripheral nerves. It is being developed as a non-opioid treatment for chronic pain conditions.